Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men
- PMID: 30600483
- DOI: 10.1007/s11604-018-0801-9
Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men
Abstract
Purpose: To clarify clinicopathological features of false-negative clinically significant prostate cancer (csPC) at multiparametric prostate MRI (mpMRI).
Methods: 95 patients with 139 csPC undergoing 3T mpMRI before radical prostatectomy were included. Two radiologists were independently evaluated mpMR images using PI-RADS v2. Clinicopathological findings were compared between (a) detectable and undetectable lesions using overall mpMRI criteria (o-mpMRI criteria) and (b) lesions with early enhancement effect (EEE) and lesions without EEE at DCE-MRI.
Results: The detection rate of csPS using cutoff value of category 3 or more in PI-RADS v2 for positive lesion was 72.1% (98/136 lesions). In 38 false-negative lesions with less than PI-RADS v2 category 3, the DCE-MRI detected 14 lesions. 17 undetectable lesions on o-mpMR criteria had lower PSA and D'amico risk classification, and higher tumor apparent diffusion coefficient (ADC) than those of 118 detectable lesions (p ≤ 0.048). 89 lesions with EEE showed higher PSA, tumor size, prostatectomy GS grade, frequency of lesions with GS ≥ 4 + 3 and lower tumor ADC than those in 38 lesions without EEE (p ≤ 0.046).
Conclusion: Tumor detectability of csPC with PI-RADS v2 was limited compared with o-mpMRI criteria in Japanese men. Moreover, false-negative lesions on o-mpMRI criteria were characterized as small in size, low risk and low cellularity.
Keywords: Dynamic contrast-enhanced MR imaging; Magnetic resonance imaging; Prostate cancer; Prostate imaging and reporting data system version 2; Tumor detection.
Similar articles
-
Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.J Magn Reson Imaging. 2021 Jan;53(1):283-291. doi: 10.1002/jmri.27283. Epub 2020 Jul 2. J Magn Reson Imaging. 2021. PMID: 32614123
-
Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?Int Urol Nephrol. 2018 Jan;50(1):13-19. doi: 10.1007/s11255-017-1753-1. Epub 2017 Nov 29. Int Urol Nephrol. 2018. PMID: 29188489
-
Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.Eur J Radiol. 2019 Jul;116:180-185. doi: 10.1016/j.ejrad.2019.04.012. Epub 2019 May 14. Eur J Radiol. 2019. PMID: 31153562
-
Multiparametric MRI in detection and staging of prostate cancer.Dan Med J. 2017 Feb;64(2):B5327. Dan Med J. 2017. PMID: 28157066 Review.
-
Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.Abdom Radiol (NY). 2017 Jan;42(1):278-289. doi: 10.1007/s00261-016-0871-z. Abdom Radiol (NY). 2017. PMID: 27522352 Free PMC article. Review.
Cited by
-
Short repetition time diffusion-weighted imaging improves visualization of prostate cancer.Jpn J Radiol. 2024 May;42(5):487-499. doi: 10.1007/s11604-023-01519-7. Epub 2023 Dec 21. Jpn J Radiol. 2024. PMID: 38123889 Free PMC article.
-
Synthetic DWI: contrast improvement for diffusion-weighted imaging in prostate using T1 shine-through by synthesizing images with adjusted TR and TE.MAGMA. 2025 Mar 24. doi: 10.1007/s10334-025-01243-5. Online ahead of print. MAGMA. 2025. PMID: 40126780
-
Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.World J Mens Health. 2021 Jan;39(1):38-47. doi: 10.5534/wjmh.200030. Epub 2020 Jun 24. World J Mens Health. 2021. PMID: 32648376 Free PMC article. Review.
-
Diffusion-weighted imaging in prostate cancer.MAGMA. 2022 Aug;35(4):533-547. doi: 10.1007/s10334-021-00957-6. Epub 2021 Sep 7. MAGMA. 2022. PMID: 34491467 Review.
-
Differentiating clinically significant prostate cancer from clinically insignificant prostate cancer using qualitative and semi-quantitative indices of dynamic contrast-enhanced MRI.Discov Oncol. 2024 Dec 18;15(1):770. doi: 10.1007/s12672-024-01668-9. Discov Oncol. 2024. PMID: 39692850 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous